Tech Company Financing Transactions

GlobeImmune Funding Round

Adams Harkness Ventures, Eminent Capital Partners and HealthCare Ventures participated in a $17.5 million funding round for GlobeImmune. The round was announced by the company on 3/31/2010.

Transaction Overview

Company Name
Announced On
3/31/2010
Transaction Type
Venture Equity
Amount
$17,508,500
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1450 Infinite Dr.
Louisville, CO 80027
USA
Email Address
Overview
GlobeImmune is developing Tarmogen product candidates to treat cancer and infectious diseases.
Profile
GlobeImmune LinkedIn Company Profile
Social Media
GlobeImmune Company Twitter Account
Company News
GlobeImmune News
Facebook
GlobeImmune on Facebook
YouTube
GlobeImmune on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Timothy Rodell
  Timothy Rodell LinkedIn Profile  Timothy Rodell Twitter Account  Timothy Rodell News  Timothy Rodell on Facebook
VP - Bus. Development
Kirk Christoffersen
  Kirk Christoffersen LinkedIn Profile  Kirk Christoffersen Twitter Account  Kirk Christoffersen News  Kirk Christoffersen on Facebook
VP - Finance
Jeffrey Dekker
  Jeffrey Dekker LinkedIn Profile  Jeffrey Dekker Twitter Account  Jeffrey Dekker News  Jeffrey Dekker on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/31/2010: TicketLeap.com venture capital transaction
Next: 3/31/2010: Signostics venture capital transaction

 

Share this article

 


News on VC Transactions

We document all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary